Get notified when RGNX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern, and its auditor has included a going-concern explanatory paragraph.
- Dilution (new) — New investors face immediate dilution of $7.14 per share, with the offering price far above net tangible book value, and additional dilution from outstanding options and warrants.
REGENXBIO prices $100M offering of common stock and pre-funded warrants at $9.00 per share
Filed July 17, 2026 · ~2 min read
Key Changes
-
high
REGENXBIO is selling 10,003,889 common shares at $9.00 each and 1,111,111 pre-funded warrants at $8.9999 each, for a total public offering price of about $100.0 million.
The Offering verify on EDGAR → -
high
The company estimates net proceeds of $93.7 million, or $107.8 million if underwriters fully exercise their option to purchase additional shares, after deducting underwriting discounts and expenses.
Use of Proceeds verify on EDGAR → -
medium
Net proceeds are earmarked for general corporate purposes, including clinical trials, pipeline development, working capital, and potential debt repayment or acquisitions.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.
Partner
Trade RGNX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify